Pancreatic Cancer Drug Daraxonrasib Nearly Doubled Survival In Phase 3
A clinical trial published in the New England Journal of Medicine in May 2026, and supplemented by Phase 3 data announced in April that nearly doubled survival in patients with advanced pancreatic
Follow Us